Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer (NCT00003309) | Clinical Trial Compass
CompletedPhase 2
Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer
United States33 participantsStarted 1999-05-04
Plain-language summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by radiation therapy in treating adult patients with brain cancer.
Who can participate
Age range18 Years – 120 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed central nervous system cancer including:
* Medulloblastoma with either local residual disease of greater than 1 cm\^2 on MRI following resection or evidence of metastases (M1-4)
* Other primitive neuroectodermal tumors
* Ependymoma with evidence of subarachnoid metastases
* Must have less than 1 cm of midline shift or no acute elevated intercranial pressure
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* WBC greater than 4,000/mm\^3
* Platelet count greater than 125,000/mm\^3
* Hemoglobin greater than 10 g/dL
* No preexisting hematologic condition that would increase toxicity or limit ability to comply with evaluations and follow-up
Hepatic:
* Bilirubin less than 2 times upper limit of normal (ULN)
* SGOT less than 2 times ULN
* Alkaline phosphatase less than 2 times ULN
* No preexisting hepatic condition that would increase toxicity or limit ability to comply with evaluations and follow-up
Renal:
* Creatinine greater than 70 mL/min
* No preexisting renal condition that would increase toxicity or limit ability to comply with evaluations and follow-up
Pulmonary:
* No history of significant pulmonary disease or, if there is preexisting pulmonary disease, then DLCO greater than 60% of predicted
* No preexisting pulmonary condition that would increase toxicity or limit ability to comply with evaluations and follow-up
Other:
* No…